Background Despite vaccination, many remain vulnerable to coronavirus disease 2019
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …

Objective To evaluate whether favipiravir reduces the time to viral clearance as documented
by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild …

Background Favipiravir possesses high utility for treating patients with COVID-19. However,
research examining the efficacy and safety of favipiravir for patients with COVID-19 is …

Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-
CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …

Favipiravir has demonstrated efficacy against the SARS-CoV-2 virus in several preliminary
studies. This study aimed to evaluate the efficacy and safety of favipiravir for treatment of …

Background COVID-19 has overwhelmed health services globally. Oral antiviral therapies
are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the …

We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia
and its effects towards viral clearance, clinical condition, and risk of COVID-19 pneumonia …

Background Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19)
but currently available agents are expensive. Favipiravir is routinely used in many countries …